Product information and disease descriptionProduct description
Phase of product development
10 evidence topics · 9 sources
Regulatory status: Submission planned; registrational phase 3 EMERGE trial ongoing, with top-line results expected in the second half of 2028
Launch
No evidence found.
Planned update to EMERGE top-line guidance by the end of 2027
Orphan drug designation for myasthenia gravis, May 2026
Fast track or breakthrough therapy designation for generalized myasthenia gravis
No evidence found.